Skip to main content
Equibles

Barbara Duncan

Board Member

Atea Pharmaceuticals, Inc. (AVIR)

Equibles does not estimate personal net worth.

Get an email with a short summary when Atea Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get AVIR alerts

About Barbara Duncan

Barbara Duncan is recorded as Board Member at Atea Pharmaceuticals, Inc. (AVIR) since January 1, 2020. The newest filing on record that lists Barbara Duncan as Board Member at Atea Pharmaceuticals, Inc. (AVIR) is dated April 27, 2026. Barbara Duncan was last confirmed as Board Member at Ovid Therapeutics Inc. (OVID) in a filing dated April 24, 2024. Earlier roles on record: Board Member at Adaptimmune Therapeutics PLC (ADAPY) until June 1, 2023. Adaptimmune Therapeutics PLC reported in an 8-K filed June 1, 2023 that Barbara Duncan resigned as director, effective June 1, 2023. Atea Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Atea Pharmaceuticals, Inc. includes Jean-Pierre Sommadossi (CEO and Board Member), Andrea Corcoran (CFO), Wayne Foster (Chief Accounting Officer) and 7 others.

“In connection with the Merger and effective as of the Effective Time, Barbara Duncan and James Noble resigned as directors of Adaptimmune.”
Adaptimmune Therapeutics PLC Form 8-K, filed June 1, 2023 · Read the filing

Affiliation history

Company network

Leadership on record at Atea Pharmaceuticals, Inc.

Recent activity